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African non human primates are natural hosts of SIV. The
infection is non-pathogenic despite plasma viral load lev-
els similar to those in HIV-1 infected humans and SIV-
mac-infected macaques (MAC) progressing towards AIDS.
The most striking difference between non-pathogenic SIV
and pathogenic HIV-1/SIVmac infections is the lack of
chronic T cell activation in natural hosts. In HIV and SIV-
mac infections, chronic T cell activation is known to drive
CD4+T cell depletion. Intense research efforts are world-
wide put on the search of the mechanisms that can control
chronic T cell activation in HIV/SIV infections. Innate
immune responses play a determinant role in the regula-
tion of T cell activation profiles. Type I interferons (IFN-I)
are part of the first-wave response of the innate immune
system in viral infections. We compared the IFN-I
responses between pathogenic (MAC) and non-patho-
genic SIV infections (African Green monkey, AGM) at the
level of blood and lymph nodes (LN) during the early and
chronic stage of infection. During the acute SIVagm infec-
tion, we detected high amounts of IFN-α in the plasma of
AGMs, although the mean levels at the peak were three
times lower than in MAC. The microarray data revealed a
rapid and strong up-regulation of type I Interferon-Stimu-
lated Genes (ISG) in AGMs during acute SIVagm infec-
tion. ISGs denote the in vivo activity of IFN-I. Using a
functional assay, we demonstrated that low IFN-α con-
centrations (50 times lower than the IFN-α levels in
plasma at the peak) were sufficient to induce strong ISG
responses in AGM and MAC cells. Surprisingly, our direct
comparison of blood and LNs showed that ISG induction
was broader in blood of AGMs than in MAC, while in LN,
it was the contrary. Thus, in AGMs, less ISG were induced
in LNs as compared to MAC already during the acute
phase of infection. Moreover, our tight kinetic analysis
showed that this ISG expression was efficiently controlled
after day 28 post-infection in AGMs, while in MAC the
ISGs expression remained uncontrolled. Finally, we iden-
tified genes that were differentially expressed between the
two species and which might be involved in the discrimi-
nating responses. Altogether, this shows that AGMs are
capable to mount a well coordinated and efficient regula-
tive response to innate immune activation.
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